Brought to you by 
GSK licenses Roche's late-stage osteoporosis drug
21 Mar 2002
Executive Summary
GlaxoSmithKline licensed exclusive worldwide co-development and co-promotion rights, excluding Japan, to Roche's ibandronate, which is in Phase III trials to treat and prevent postmenopausal osteoporosis.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com